miR‑4730 suppresses the progression of liver cancer by targeting the high mobility group A1 pathway

Furuke,Hirotaka; Konishi,Hirotaka; Arita,Tomohiro; Kataoka,Satoshi; Shibamoto,Jun; Takabatake,Kazuya; Takaki,Wataru; Shimizu,Hiroki; Yamamoto,Yusuke; Morimura,Ryo; Komatsu,Shuhei; Shiozaki,Atsushi; Ikoma,Hisashi; Otsuji,Eigo

doi:10.3892/ijmm.2022.5139

miR‑4730 suppresses the progression of liver cancer by targeting the high mobility group A1 pathway

Authors:
- Hirotaka Furuke
- Hirotaka Konishi
- Tomohiro Arita
- Satoshi Kataoka
- Jun Shibamoto
- Kazuya Takabatake
- Wataru Takaki
- Hiroki Shimizu
- Yusuke Yamamoto
- Ryo Morimura
- Shuhei Komatsu
- Atsushi Shiozaki
- Hisashi Ikoma
- Eigo Otsuji
View Affiliations

Affiliations: Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto 602‑8566, Japan
Published online on: April 28, 2022 https://doi.org/10.3892/ijmm.2022.5139
Article Number: 83
Copyright: © Furuke et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

As liver cancer (LC) is the sixth most commonly diagnosed malignancy, it is necessary to elucidate the molecular mechanisms responsible for LC progression. MicroRNAs (miRNAs/miRs) play crucial roles in tumor progression by regulating target gene expression. The present study assessed miRNA‑4730 expression and function in LC. The effects of miR‑4730 overexpression were examined in LC cell lines, and the target genes of miR‑4730 were evaluated using microarray analysis and TargetScan data. In addition, the association between miR‑4730 expression in tissue samples and the prognosis of 70 patients with LC was evaluated. miR‑4730 expression was suppressed in LC tissues and cell lines. miR‑4730 overexpression suppressed cell proliferation and cell cycle progression and promoted apoptosis. High mobility group A1 (HMGA1) was revealed as the direct target of miR‑4730 using luciferase reporter assay, and the inhibition of downstream integrin‑linked kinase (ILK) expression and Akt or glycogen synthase kinase 3β (GSK3β) phosphorylation was confirmed. The lower expression of miR‑4730 in tissue samples was significantly associated with a worse recurrence‑free survival of patients with LC. On the whole, miR‑4730 suppressed tumor progression by directly targeting HMGA1 and inhibiting the ILK/Akt/GSK3β pathway. miR‑4730 thus has potential for use as a prognostic marker and may prove to be a therapeutic target for miRNA‑based therapies.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Forner A, Llovet JM and Bruix J: Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
3	Altekruse SF, Henley SJ, Cucinelli JE and McGlynn KA: Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol. 109:542–553. 2014. View Article : Google Scholar : PubMed/NCBI
4	Zhang G, Li R, Deng Y and Zhao L: Conditional survival of patients with hepatocellular carcinoma: Results from the Surveillance, Epidemiology, and End Results registry. Expert Rev Gastroenterol Hepatol. 12:515–523. 2018. View Article : Google Scholar : PubMed/NCBI
5	Xu L, Kim Y, Spolverato G, Gani F and Pawlik TM: Racial disparities in treatment and survival of patients with hepatocellular carcinoma in the United States. Hepatobiliary Surg Nutr. 5:43–52. 2016.PubMed/NCBI
6	Villanueva A: Hepatocellular Carcinoma. N Engl J Med. 380:1450–1462. 2019. View Article : Google Scholar : PubMed/NCBI
7	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
8	Link A and Kupcinskas J: MicroRNAs as non-invasive diagnostic biomarkers for gastric cancer: Current insights and future perspectives. World J Gastroenterol. 24:3313–3329. 2018. View Article : Google Scholar : PubMed/NCBI
9	Harada K, Baba Y, Ishimoto T, Shigaki H, Kosumi K, Yoshida N, Watanabe M and Baba H: The role of microRNA in esophageal squamous cell carcinoma. J Gastroenterol. 51:520–530. 2016. View Article : Google Scholar : PubMed/NCBI
10	Chen B, Xia Z, Deng YN, Yang Y, Zhang P, Zhu H, Xu N and Liang S: Emerging microRNA biomarkers for colorectal cancer diagnosis and prognosis. Open Biol. 9:1802122019. View Article : Google Scholar : PubMed/NCBI
11	Rawat M, Kadian K, Gupta Y, Kumar A, Chain PSG, Kovbasnjuk O, Kumar S and Parasher G: MicroRNA in pancreatic cancer: From biology to therapeutic potential. Genes (Basel). 10:7522019. View Article : Google Scholar
12	Oura K, Morishita A and Masaki T: Molecular and functional roles of MicroRNAs in the progression of hepatocellular carcinoma-A review. Int J Mol Sci. 21:83622020. View Article : Google Scholar
13	Zhang L, Yang L, Liu X, Chen W, Chang L, Chen L, Loera S, Chu P, Huang WC, Liu YR and Yen Y: MicroRNA-657 promotes tumorigenesis in hepatocellular carcinoma by targeting transducin-like enhancer protein 1 through nuclear factor kappa B pathways. Hepatology. 57:1919–1930. 2013. View Article : Google Scholar
14	Song Z, Yu Z, Chen L, Zhou Z, Zou Q and Liu Y: MicroRNA-1181 supports the growth of hepatocellular carcinoma by repressing AXIN1. Biomed Pharmacother. 119:1093972019. View Article : Google Scholar : PubMed/NCBI
15	Wong QW, Lung RW, Law PT, Lai PB, Chan KY, To KF and Wong N: MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology. 135:257–269. 2008. View Article : Google Scholar : PubMed/NCBI
16	Wang R, Zhao N, Li S, Fang JH, Chen MX, Yang J, Jia WH, Yuan Y and Zhuang SM: MicroRNA-195 suppresses angiogenesis and metastasis of hepatocellular carcinoma by inhibiting the expression of VEGF, VAV2, and CDC42. Hepatology. 58:642–653. 2013. View Article : Google Scholar : PubMed/NCBI
17	Yang W, Ju HY and Tian XF: Hsa-miR-4730 as a new and potential diagnostic and prognostic indicators for pancreatic cancer. Eur Rev Med Pharmacol Sci. 24:8801–8811. 2020.PubMed/NCBI
18	Union for International Cancer Control: TNM Classification of Malignant Tumours. Brierley JD, Gospodarowicz MK and Wittekind C: 8th edition. John Wiley & Sons, Inc; Hoboken, NJ: 2017
19	The Japan Society of Hepatology: Clinical Practice Guidelines for Hepatocellular Carcinoma 2017. Kanehara & Co Ltd; Tokyo: 2017
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
21	Liu L, Zhang S, Hu L, Liu L, Guo W and Zhang J: HMGA1 participates in MHCC97H cell proliferation and invasion through the ILK/Akt/GSK3β signaling pathway. Mol Med Rep. 16:9287–9294. 2017. View Article : Google Scholar : PubMed/NCBI
22	Fusco A and Fedele M: Roles of HMGA proteins in cancer. Nat Rev Cancer. 7:899–910. 2007. View Article : Google Scholar : PubMed/NCBI
23	Chiappetta G, Avantaggiato V, Visconti R, Fedele M, Battista S, Trapasso F, Merciai BM, Fidanza V, Giancotti V, Santoro M, et al: High level expression of the HMGI (Y) gene during embryonic development. Oncogene. 13:2439–2446. 1996.PubMed/NCBI
24	Wang Y, Hu L, Zheng Y and Guo L: HMGA1 in cancer: Cancer classification by location. J Cell Mol Med. 23:2293–2302. 2019. View Article : Google Scholar : PubMed/NCBI
25	Sumter TF, Xian L, Huso T, Koo M, Chang YT, Almasri TN, Chia L, Inglis C, Reid D and Resar LM: The high mobility group A1 (HMGA1) transcriptome in cancer and development. Curr Mol Med. 16:353–393. 2016. View Article : Google Scholar : PubMed/NCBI
26	Shi M, Lv X, Zhu M, Dong Y, Hu L, Qian Y, Fan C and Tian N: HMGA1 promotes hepatocellular carcinoma proliferation, migration, and regulates cell cycle via miR-195-5p. Anticancer Drugs. 33:e273–e285. 2022. View Article : Google Scholar
27	Wan T, Zheng J, Yao R, Yang S, Zheng W and Zhou P: LncRNA DDX11-AS1 accelerates hepatocellular carcinoma progression via the miR-195-5p/MACC1 pathway. Ann Hepatol. 20:1002582021. View Article : Google Scholar
28	Liu LX, Liu B, Yu J, Zhang DY, Shi JH and Liang P: SP1-induced upregulation of lncRNA CTBP1-AS2 accelerates the hepatocellular carcinoma tumorigenesis through targeting CEP55 via sponging miR-195-5p. Biochem Biophys Res Commun. 533:779–785. 2020. View Article : Google Scholar : PubMed/NCBI
29	Huang D, Wei Y, Zhu J and Wang F: Long non-coding RNA SNHG1 functions as a competitive endogenous RNA to regulate PDCD4 expression by sponging miR-195-5p in hepatocellular carcinoma. Gene. 714:1439942019. View Article : Google Scholar : PubMed/NCBI
30	Reeves R: Molecular biology of HMGA proteins: Hubs of nuclear function. Gene. 277:63–81. 2001. View Article : Google Scholar : PubMed/NCBI
31	Chan J, Ko FC, Yeung YS, Ng IO and Yam JW: Integrin-linked kinase overexpression and its oncogenic role in promoting tumorigenicity of hepatocellular carcinoma. PLoS One. 6:e169842011. View Article : Google Scholar : PubMed/NCBI
32	Revathidevi S and Munirajan AK: Akt in cancer: Mediator and more. Semin Cancer Biol. 59:80–91. 2019. View Article : Google Scholar : PubMed/NCBI
33	Spokoini R, Kfir-Erenfeld S, Yefenof E and Sionov RV: Glycogen synthase kinase-3 plays a central role in mediating glucocorticoid-induced apoptosis. Mol Endocrinol. 24:1136–1150. 2010. View Article : Google Scholar : PubMed/NCBI
34	Koundouros N and Poulogiannis G: Phosphoinositide 3-Kinase/Akt signaling and redox metabolism in cancer. Front Oncol. 8:1602018. View Article : Google Scholar : PubMed/NCBI
35	Nakanishi F, Ohkawa K, Ishida H, Hosui A, Sato A, Hiramatsu N, Ueda K, Takehara T, Kasahara A, Sasaki Y, et al: Alteration in gene expression profile by full-length hepatitis B virus genome. Intervirology. 48:77–83. 2005. View Article : Google Scholar : PubMed/NCBI